BRIEF published on 09/23/2025 at 10:05, 6 months 16 days ago HeartBeat.bio Collaborates with Boehringer Ingelheim on Gene Therapies Cardiovascular Health Research Collaboration Gene Therapies Heart Muscle Disorders Cardioid Platform
PRESS RELEASE published on 09/23/2025 at 10:00, 6 months 16 days ago HeartBeat.bio Joins Forces with Boehringer Ingelheim to Advance Gene Therapies for Inherited Heart Muscle Disorders HeartBeat.bio collaborates with Boehringer Ingelheim to develop gene therapies for genetic cardiomyopathies, addressing unmet needs in heart health Heart Health Gene Therapy Boehringer Ingelheim HeartBeat.bio Cardiomyopathies
PRESS RELEASE published on 11/02/2023 at 11:00, 2 years 5 months ago HeartBeat.bio raises € 4.5 million in Pre-Series A financing to drive development of organoid screening platform for cardiac drug discovery
Published on 04/09/2026 at 16:00, 48 minutes ago Banff Half Marathon Completes 2025 Emissions Assessment, Supporting Climate Action with Karbon-X
Published on 04/09/2026 at 14:40, 2 hours 8 minutes ago Silver X Delivers Production Growth During the First Quarter of 2026
Published on 04/09/2026 at 14:00, 2 hours 48 minutes ago Orogen Royalties Announces Mineral Reserve and Resource Update on Producing Ermitaño Royalty
Published on 04/09/2026 at 13:30, 3 hours 18 minutes ago Datametrex Receives $6M Purchase Order for Data Centre from Fortune 500 Conglomerate
Published on 04/09/2026 at 13:30, 3 hours 18 minutes ago ESGold Advances Toward Production and Exploration Drilling as Mill Buildout Progresses in Parallel
Published on 04/09/2026 at 15:40, 1 hour 8 minutes ago Form 8.3 - The Vanguard Group, Inc.: LondonMetric Property plc
Published on 04/09/2026 at 15:39, 1 hour 8 minutes ago Form 8.3 - The Vanguard Group, Inc.: Schroders plc
Published on 04/09/2026 at 15:39, 1 hour 9 minutes ago Form 8.3 - The Vanguard Group, Inc.: British Land Company plc, The
Published on 04/09/2026 at 15:57, 50 minutes ago Filing of CNP Assurances SA 2025 universal registration document and 2025 Solvency and Financial Condition Reports
Published on 04/09/2026 at 07:00, 9 hours 48 minutes ago bioMérieux Unveils its BIOFIRE® SPOTFIRE® Molecular Testing Solution for the Pharmaceutical Industry, Redefining Rapid Mycoplasma Testing
Published on 04/08/2026 at 18:02, 22 hours 46 minutes ago Publication of the 2025 Universal Registration Document
Published on 04/08/2026 at 17:45, 23 hours 3 minutes ago DISCLOSURE OF SHARE CAPITAL AND VOTING RIGHTS
Published on 04/08/2026 at 12:58, 1 day 3 hours ago EURAZEO IS ASSIGNED A BBB CREDIT RATING (STABLE OUTLOOK) BY S&P AND A BBB CREDIT RATING (STABLE OUTLOOK) BY FITCH
